FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
They complement each other: Just like a king and queen work together to rule a kingdom, technology and methodology are essential for success in HealthTech. Technology provides the potential, while methodology unlocks that potential.
Read the full article here.
Reid Hoffman became a billionaire from his business social-working company, and has made lucrative bets on companies including Airbnb and Zynga while also backing nuclear fusion startup Helion Energy.
Now Hoffman is diving into the health care, which he describes…